Moberg Pharma Q4’2024: Primary focus on Europe - Redeye

Redeye comments on the Q4 report from Moberg Pharma. The sales came in line with our expectations at SEK 1.0m. Gross margins were a bit lower while the costs were aligned apart from the intangible asset impairment of SEK 300m. The strategy to focus on the EU first is affirmed. The result adjusted for the impairment was slightly below our expectations, although there was not a considerable difference. Based on this report, we will not make significant changes to our estimates as the strategic decision to concentrate on the EU was expected. We will adjust our estimates for the Norwegian sales start as indicated earlier and for South Korea. Based on this report, we do not expect more than a slight upwards adjustment to our Base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1074411/moberg-pharma-q42024-primary-focus-on-europe?utm_source=finwire&utm_medium=RSS